Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.

ABSTRACT:

Purpose

Isocitrate dehydrogenase (IDH) 1 and IDH2 mutations (IDH1/2mt) are frequent in glioma. Preclinical studies suggest IDH1/2mts confer "BRCAness" phenotype, a vulnerability that can be targeted through PARP inhibition. To test this hypothesis, we conducted a multicenter study of olaparib monotherapy in patients with IDH1/2mt gliomas.

Methods

Patients with recurrent, contrast-enhancing IDH1/2mt gliomas were enrolled in a two-step phase II trial; the primary endpoint was overall response rate per Response Assessment in Neuro-Oncology (RANO) criteria. Olaparib 300 mg orally twice daily was given.

Results

A total of 15 evaluable patients were enrolled. Histology was astrocytoma (N = 12) and oligodendroglioma (

SUBMITTER: Fanucci K 

PROVIDER: S-EPMC10035510 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature